Role of suPAR in Periodontitis and CVD

NCT ID: NCT04335344

Last Updated: 2020-04-07

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

326 participants

Study Classification

OBSERVATIONAL

Study Start Date

2015-02-15

Study Completion Date

2020-02-25

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

soluble urokinase-type plasminogen activator receptor (suPAR) plays a key role in endothelial function and may be a link for the known interaction of periodontitis and cardiovascular disease (CVD). The investigators compared the impact of gingival health, periodontitis (CP), CHD or of both diseases (CP+CHD) on saliva and serum suPAR levels.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The aim of this study was to evaluate a possible association between both saliva and serum suPAR levels in patients with CP and with CVD and if the serum suPAR levels are mediated by serum CRP.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Metabolic Disturbance Periodontal Diseases

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Control

Healthy patients

Observation of suPAR plasma and salivary levels

Intervention Type OTHER

Evaluation of suPAR plasma level and correlation of plasma suPAR levels with periodontal and cardiovascular disease

Periodontitis

Patients with periodontitis

Observation of suPAR plasma and salivary levels

Intervention Type OTHER

Evaluation of suPAR plasma level and correlation of plasma suPAR levels with periodontal and cardiovascular disease

Cardiovascular disease

Patients with cardiovascular disease

Observation of suPAR plasma and salivary levels

Intervention Type OTHER

Evaluation of suPAR plasma level and correlation of plasma suPAR levels with periodontal and cardiovascular disease

Periodontitis + cardiovascular disease

Patients with Periodontitis + cardiovascular disease

Observation of suPAR plasma and salivary levels

Intervention Type OTHER

Evaluation of suPAR plasma level and correlation of plasma suPAR levels with periodontal and cardiovascular disease

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Observation of suPAR plasma and salivary levels

Evaluation of suPAR plasma level and correlation of plasma suPAR levels with periodontal and cardiovascular disease

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Presence of at least 15 teeth
* CP with a minimum of 40% of sites with a clinical attachment level (CAL) ≥2mm and probing depth (PD) ≥4mm;
* Presence of at least ≥2 mm of crestal alveolar bone loss verified on digital periapical radiographs
* Presence of ≥40% sites with bleeding on probing (BOP)

Exclusion Criteria

* Intake of contraceptives
* Intake of immunosuppressive or anti-inflammatory drugs throughout the last three months prior to the study
* Status of pregnancy or lactation
* Previous history of excessive drinking
* Allergy to local anaesthetic
* Intake of drugs that may potentially determine gingival hyperplasia such as Hydantoin, Nifedipine, Cyclosporin A or similar drugs.
Minimum Eligible Age

40 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Catania

OTHER

Sponsor Role collaborator

University of Messina

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Gaetano Isola, DDS, PhD

Researcher

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Giovanni Matarese

Role: STUDY_CHAIR

University of Messina

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Messina

Messina, , Italy

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Italy

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

11-18-18

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.